Journal ArticleDOI
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C. Goldberg,Paul N. Hopkins,Peter P. Toth,Christie M. Ballantyne,Daniel J. Rader,Jennifer G. Robinson,Stephen R. Daniels,Samuel S. Gidding,Sarah D. de Ferranti,Matthew K. Ito,Mary P. McGowan,Patrick M. Moriarty,William C. Cromwell,Joyce L. Ross,Paul Ziajka +14 more
Reads0
Chats0
TLDR
This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.About:
This article is published in Journal of Clinical Lipidology.The article was published on 2011-05-01. It has received 560 citations till now. The article focuses on the topics: Familial hypercholesterolemia & Lomitapide.read more
Citations
More filters
Journal ArticleDOI
Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease.
Yating Wang,Li Shen,Danyan Xu +2 more
TL;DR: Aerobic exercise is recommended as an effective measure to improve the prognosis of individuals with coronary heart disease (CHD).
Journal ArticleDOI
Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment
TL;DR: It is concluded that FH patients harboring a null mutation have a trend to an increased risk of CVD, even if diagnosis is early established and lipid-lowering treatment instituted, and it is suggested that these individuals may benefit from the use of newly approved lipid- Lowering agents.
Journal ArticleDOI
Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
TL;DR: The combination of PCSK9 inhibitor and apo(a) antisense therapy appears the optimal strategy for mitigating residual risk of ASCVD in HeFH patients with high Lp(a).
Journal ArticleDOI
Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
Paul Lee,Robert A. Hegele +1 more
TL;DR: Despite their biochemical efficacy, clinical efficacy remains to be shown for two leading monoclonal antibodies against PSCK9, and other issues to be evaluated with these agents over the longer term include development of rare adverse effects and potential attenuation of efficacy.
Journal ArticleDOI
The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.
Sophie Béliard,Aurélie Millier,Valérie Carreau,Alain Carrié,Philippe Moulin,Alexandre Fredenrich,Michel Farnier,Gérald Luc,David Rosenbaum,Mondher Toumi,Eric Bruckert,Denis Angoulvant,S. Béliard,Franck Boccara,E. Bruckert,V. Durlach,Michel Farnier,Jean Ferrières,Régis Hankard,Michel Krempf,J.D. Lalau,G. Luc,P. Moulin,F. Paillard,Noël Peretti,A. Pradignac,Y. Pucheu,Patrick Tounian,B. Vergès,Olivier Ziegler +29 more
TL;DR: A detailed description of French heFH patients according to their CV risk is provided, comparing patients at very high risk (VHR) and patients at high risk in terms of demographic and clinical characteristics as well as biological measurements and disease management.
References
More filters
Journal ArticleDOI
Hyperlipidemia in Coronary Heart Disease II. GENETIC ANALYSIS OF LIPID LEVELS IN 176 FAMILIES AND DELINEATION OF A NEW INHERITED DISORDER, COMBINED HYPERLIPIDEMIA
TL;DR: The combined disorder was shown to be genetically distinct from familial hypercholesterolemia and familial hypertriglyceridemia for the following reasons: the distribution pattern of cholesterol and triglyceride levels in relatives of probands was unique.
Journal ArticleDOI
Lipid Screening and Cardiovascular Health in Childhood
TL;DR: The need for prevention of cardiovascular disease by following Dietary Guidelines for Americans and increasing physical activity is reemphasized and the need for pharmacologic agents and indications for treating dyslipidemia in children are reviewed.
Journal ArticleDOI
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Jorie Versmissen,Daniëlla M. Oosterveer,Mojgan Yazdanpanah,Joep C. Defesche,Dick C. Basart,Anho H Liem,Jan Heeringa,Jacqueline C.M. Witteman,P. J. Lansberg,John J.P. Kastelein,Eric J.G. Sijbrands +10 more
TL;DR: Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia.
Journal ArticleDOI
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
TL;DR: The clinical phenotype of heterozygous familial hypercholesterolemia (FH) is characterized by increased plasma levels of total cholesterol and low density lipoprotein cholesterol, tendinous xanthomata, and premature symptoms of coronary heart disease.
Journal ArticleDOI
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.
TL;DR: These guidelines have been elaborated by a group of international experts with the intention to answer the main questions about heterozygous FH (heFH) subjects that physicians worldwide face in the diagnosis and management of these patients.
Related Papers (5)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
Børge G. Nordestgaard,M. John Chapman,Steve E. Humphries,Henry N. Ginsberg,Luis Masana,Olivier S. Descamps,Olov Wiklund,Robert A. Hegele,Frederick J. Raal,Joep C. Defesche,Albert Wiegman,Raul D. Santos,Gerald F. Watts,Klaus G. Parhofer,G. Kees Hovingh,Petri T. Kovanen,Catherine Boileau,Maurizio Averna,Jan Borén,Eric Bruckert,Alberico L. Catapano,Jan Albert Kuivenhoven,Jan Albert Kuivenhoven,P. Pajukanta,Kausik K. Ray,Anton F. H. Stalenhoef,Erik S.G. Stroes,Marja-Riitta Taskinen,Anne Tybjærg-Hansen +28 more
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel,Eric Bruckert,Henry N. Ginsberg,Frederick J. Raal,Raul D. Santos,Robert A. Hegele,Jan Albert Kuivenhoven,Børge G. Nordestgaard,Olivier S. Descamps,Elisabeth Steinhagen-Thiessen,Anne Tybjærg-Hansen,Gerald F. Watts,Maurizio Averna,Catherine Boileau,Jan Borén,A.L. Catapano,Joep C. Defesche,G. Kees Hovingh,Steve E. Humphries,Petri T. Kovanen,Luis Masana,Päivi Pajukanta,Klaus G. Parhofer,Kausik K. Ray,Anton F. H. Stalenhoef,Erik S.G. Stroes,Marja-Riitta Taskinen,Albert Wiegman,Olov Wiklund,M. John Chapman +29 more
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆
Alberico L. Catapano,Zeljko Reiner,Guy De Backer,Ian D. Graham,Marja-Riitta Taskinen,Olov Wiklund,Stefan Agewall,Eduardo Alegria,M. John Chapman,Paul N. Durrington,Serap Erdine,Julian Halcox,Richard J. Hobbs,John Kjekshus,Pasquale Perrone Filardi,Gabriele Riccardi,Robert F. Storey,David R. Wood +17 more